Immuron Limited (IMRN) News

Immuron Limited (IMRN): $1.98

-0.01 (-0.58%)

POWR Rating

Component Grades








Add IMRN to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




#203 of 238

in industry

Filter IMRN News Items

IMRN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IMRN News Highlights

  • For IMRN, its 30 day story count is now at 4.
  • Over the past 22 days, the trend for IMRN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about IMRN are DRUG, ASX and HOUR.

Latest IMRN News From Around the Web

Below are the latest news stories about IMMURON LTD that investors may wish to consider to help them evaluate IMRN as an investment opportunity.

Immuron Initiates Recruitment of Travelan® Clinical Study

Highlights: Immuron receives approval from U.S. Army Medical Research and Development CommandRecruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM) Clinical Trial is in progressClinical Trial to examine a dosing regimen for Travelan® more suited to the US military will commence shortlyTravelan® is known to protect against the onset of Travelers diarrhea (TD), the most common illness reported by travelersThis is one of three Phase 2 studies with FDA

Yahoo | May 30, 2023

Immuron Limited Announces Participation in the LD Micro Invitational XIII

Melbourne, Australia--(Newsfile Corp. - May 16, 2023) - Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 meetings. Immuron Limited is scheduled to present on June 6th at 02:00 PM PT. Steven Lydeamore, ...

Yahoo | May 16, 2023

Why Is Immuron (IMRN) Stock Up 67% Today?

Immuron (IMRN) stock is gaining on Monday thanks to an update from the Food and Drug Administration (FDA) on a clinical hold.

William White on InvestorPlace | May 8, 2023

Palantir (PLTR) Stock Pops Ahead of Earnings

Palantir (PLTR) stock is a hot topic on Monday as investors prepare for the company to report earnings after today's closing bell.

William White on InvestorPlace | May 8, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Pre-market stock movers are a hot topic on Monday as we dive into the biggest winners and losers traders need to know about this morning!

William White on InvestorPlace | May 8, 2023

Why Is Aptorum (APM) Stock Down 16% Today?

Aptorum (APM) stock is falling on Monday after the biopharmaceutical company received a delisting notice from the Nasdaq.

William White on InvestorPlace | May 8, 2023

Why Is Tupperware Brands (TUP) Stock Down 8% Today?

Tupperware Brands (TUP) stock is taking a beating on Monday after the company said it's exploring strategic alternatives.

William White on InvestorPlace | May 8, 2023

FDA Lifts Clinical Hold From Immuron's New Campylobacter ETEC Therapeutic Study

Immuron Limited (NASDAQ: IMRN) has announced that the U.S. Naval Medical Research Center (NMRC) has received FDA approval to proceed with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The FDA has removed a clinical hold on the Investigational New Drug (IND) application allowing the NMRC to proceed with its plans to evaluate the efficacy of the hyperimmune product to prevent infectious

Yahoo | May 8, 2023

Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation

Highlights: U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND applicationUS Naval Medical Research Centre (NMRC) satisfactorily addressed all clinical hold issues identified by the FDAIND to evaluate the efficacy of new Campylobacter ETEC Therapeutic in two human Phase 2 clinical trials is now activeOne trial will focus on the ability of the hyperimmune product to prevent infectious diarrhoea caused by ETEC The second trial will focus on prote

Yahoo | May 8, 2023

Immuron CEO, Steven Lydeamore to present at Coffee Microcaps

MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide a copy of the presentation being made today in Melbourne at Coffee Microcaps Conference by our Chief Executive Officer, Steven Lydeamore. A copy of the presentation slide deck is available

Yahoo | May 2, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6605 seconds.